| abstract |
The present invention relates to a pharmaceutical composition comprising a 2-carboxamide cyclominourea derivative, a phosphatidylinositol-3-kinase (PI3K) inhibitor compound or a pharmaceutically acceptable salt thereof, and at least one mammalian rapamycin target (mTOR) A pharmaceutical combination comprising a salt; A pharmaceutical composition comprising such a combination; And proliferative diseases, and more particularly, the use of such a combination in the treatment of mammalian rapamycin target (mTOR) kinase dependent diseases. |